46. 悪性関節リウマチ
[臨床試験数:4,183,薬物数:2,538(DrugBank:401),標的遺伝子数:183,標的パスウェイ数:219

Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01211249
(ClinicalTrials.gov)
October 201028/9/2010GLPG0259 in Methotrexate-refractory Rheumatoid ArthritisRandomized, Double-Blind, Placebo-Controlled, Multicenter, Exploratory Phase II Study to Compare Three Dose Regimens of GLPG0259 vs Placebo, in Combination With Methotrexate, Administered for 12 Weeks to Subjects With Active Rheumatoid Arthritis and an Inadequate Response to MethotrexateRheumatoid ArthritisDrug: GLPG0259 oral capsule;Drug: Placebo;Drug: GLPG0259 (Part B);Drug: Placebo (Part B)Galapagos NVNULLCompleted18 Years70 YearsBoth30Phase 2Belgium;Netherlands;Poland;Russian Federation;Ukraine
2NCT00291928
(ClinicalTrials.gov)
February 200514/2/2006HuMax-CD20 in Active Rheumatoid Arthritis, Phase I/IIA Double-blind, Randomized, Placebo Controlled, Dose Escalation, Multi-centerphase I/II Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20antibody, in Patients With Active Rheumatoid Arthritis Who Have Previously Failedone or More Disease Modifying Anti-rheumatic DrugsArthritis, RheumatoidDrug: Part A;Drug: Part BGlaxoSmithKlineNULLCompleted18 YearsN/ABoth201Phase 2United States;Denmark;Finland;France;Hungary;Poland;United Kingdom